92 results on '"Scheulen, M. E."'
Search Results
2. Antineoplastisch wirksame Substanzen
3. Hochdosistherapiekonzepte
4. In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy
5. In Vitro Modulation of Multidrug Resistance by BIBW22BS in Blasts of De Novo or Relapsed or Persistent AML
6. Neue Entwicklungen in der Tumortherapie
7. Antineoplastisch wirksame Substanzen
8. Continuous Intravenous Pentoxifylline in Bone Marrow Transplant Recipients: First Results of a Pilot Study
9. Cellular Pharmacokinetics of Daunomycin in Human Leukemic Blasts In Vitro and In Vivo
10. Tumor, Organ and Plasma Pharmacology of Cytostatic Drugs in the Nude Mouse
11. Cellular Pharmacokinetics of Daunomycin in Human Leukemic Blasts In Vitro and In Vivo
12. Behandlungsergebnisse bei 140 Patienten mit nicht-seminomatösen Hodentumoren des klinischen Stadiums II
13. Prognostische Faktoren bei Patienten mit fortgeschrittenen nichtseminomatösen Hodenkarzinomen
14. Kumulative Anthracyclin-Kardiotoxizität. Möglichkeiten für eine kardioselektive Protektion durch Begleittherapie mit Isozitrat und Niacin
15. Biochemische Ursachen der kumulativen Anthracyclin-Kardiotoxizität — Ansatzpunkte für eine kardioprotektive Begleittherapie?1
16. Cytoskeletal Organization in Acute Leukemias
17. Chemotherapy of Disseminated Non-Seminomatous Testicular Cancer and Metastatic Seminoma with Ifosfamide/Mesna1
18. The Role of Acute Lipid Peroxidation in Doxorubicin Cardiotoxicity
19. Determination of the Cellular Uptake of Daunorubicin in Human Leukemia in vivo: Method of Examination and First Results
20. Bedeutung der Tumormarker α1-Fetoprotein und β-HCG bei der Stadieneinteilung maligner Hodentumoren
21. Hämatologie/Onkologie
22. Neues Konzept in der Behandlung inoperabler Bronchialkarzinome
23. cis-Dichlorodiaminplatinum(II) (DDP) bei refraktären soliden Tumoren — Eine Phase II-Studie
24. Autologous Bone Marrow Transplantation. The Influence of Prolonged Cytotoxic Chemotherapy
25. Onkologie I
26. Sequentiell alternierende Chemotherapie nichtseminomatöser Hodentumoren mit Velbe/Bleomycin und Adriamycin/cis-Platinum. Ergebnisse einer prospektiven Studie bei 211 Patienten
27. Untersuchung zellulárer Mechanismen der Adriamycin-Resistenz bei vier Ehrlich-Aszites-Tumorzell-Linien*
28. Raynaud-Syndrom
29. Preclinical Chemosensitivity Studies with Human Soft Tissue Sarcomas in Nude Mice
30. Adjuvante zytostatische Behandlung maligner Hodentumoren — Indikationen und Erfolgschancen
31. Therapieergebnisse bei 183 Patienten mit nicht-seminomatösen Hodentumoren des Stadiums II
32. Behandlung prognostisch ungünstiger nichtseminomatöser Hodenkarzinome mit Cisplatin, Ifosfamid und Bleomycin (PIB)
33. Antineoplastische wirksame Substanzen — Allgemeiner Teil
34. Hochdosistherapien
35. Antineoplastische wirksame Substanzen — Dosismodifikation
36. Antineoplastische wirksame Substanzen — Spezieller Teil
37. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
38. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
39. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
40. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
41. A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function.
42. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study.
43. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
44. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
45. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
46. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.
47. Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC)
48. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
49. Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study
50. Kombinierte Chemo- und Radiotherapie bei inoperablem kleinzellig-anaplastischem Bronchialkarzinom: Verlaufsanalyse bei 50 Patienten* 1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.